SYMBOL:

    Up to 100 tickers separated by a space .....Watch Post-Market activities
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
AFFYMAX
(NQPK:AFFY Last Sale: 1.48 )
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQPK: (AFFY : $1.48)
$36 million Market Cap at September 12, 2013
Employs 140.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
4001 Miranda Avenue Research Report Earnings Snapshot - Last 05/09/17
Palo Alto, CA 94304 Fact Sheet
Phone: 650-812-8700 Financial Statements
Peer Comparison
Annual Reports

Arlene M. Morris, CEO/Pres., Paul B. Cleveland, CFO
June 21, 2010, 4 late-stage studies of experimental anemia drug Hematide showed heart safety risks. The drug is being co-developed with Japan's Takeda Pharmaceutical Co Ltd. IPO at $25 December 14, 2006. Raised $92.5 million, selling 3.7 million shares, 26% of the outstanding. Lead Manager: Morgan Stanley.
Historical Charts    Technical Analysis
No Historical Data available for AFFY

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common AFFY $1.48 $ 0 $1.45 $1.55 355,704 $.841 $2.03 24,048
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $35,591

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex